Connect with us


Pharma Company Sees Positive Results in Dry-Eye Drug Studies

The goal is to promote natural tear film production.




PRINCETON, NJ — Oyster Point Pharma Inc. announced results from two studies evaluating therapies for the treatment of dry eye disease.

The Phase 2b clinical trials, presented at the Ophthalmology Innovation Summit meeting in Chicago, demonstrated improvement in Schirmer’s score and multiple measures of eye dryness symptoms, according to a press release from the company.

“The results announced today demonstrate the potential clinical benefits of the innovative therapeutics Oyster Point Pharma is developing,” said Dr. Edward Holland, professor of ophthalmology, University of Cincinnati, and member of Oyster Point Pharma’s medical advisory board. “There is a significant need for a novel treatment approach for Dry Eye Disease. A therapeutic that can help patients to produce their own natural tear film has the potential to benefit a broad population of patients with Dry Eye Disease.”

Dr. Jeffrey Nau, CEO of Oyster Point Pharma, said, “We are excited about the ability for both of our investigational compounds to show improvements in both the signs and symptoms of Dry Eye Disease. We look forward to initiating a Phase 3 program in Dry Eye Disease in 2019 after discussion with regulatory authorities.”

OC-01 and OC-02, Oyster Point’s lead product candidates, are nicotinic acetylcholine receptor (nAChR) agonists that bind specifically to receptors on the trigeminal nerve. Both compounds are administered as a nasal spray and are “potential first-in-class, ocular surface-sparing treatments designed to stimulate the trigeminal parasympathetic pathway to promote natural tear film production,” according to the release.

OC-01 and OC-02 were well-tolerated with no significant ocular adverse events or drug-related serious adverse events. Adverse events were similar in both studies. The most common adverse events included sneeze, cough, and nose and throat irritation. These events were mild, self-limiting, and resolved immediately following administration.




The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines






Get the most important news and business ideas for eyecare professionals every weekday from INVISION.


Most Popular